Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994944 | 1.00 | USP30 (0.44) | USP30USP2SMN1; SMN2RECQLSMARCA2 | |
| SCHEMBL9978161 | 1.00 | USP30 (0.44) | USP30USP2SMN1; SMN2RECQLSMARCA2 | |
| SCHEMBL2943987 | 0.81 | USP30 (0.43) | USP30USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL2954128 | 0.81 | USP30 (0.43) | USP30USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL780002 | 0.81 | USP30 (0.43) | USP30USP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL23422324 | 0.80 | USP30 (0.47) | USP30USP2SMN1; SMN2SMARCA2SMARCA4 | |
| SCHEMBL14815454 | 0.80 | USP30 (0.47) | USP30USP2SMN1; SMN2SMARCA2SMARCA4 | |
| SCHEMBL31027198 | 0.80 | USP30 (0.47) | USP30USP2SMN1; SMN2SMARCA2SMARCA4 | |
| SCHEMBL1441275 | 0.79 | USP2 (0.48) | USP30USP2SMN1; SMN2RECQLPIK3CD | |
| SCHEMBL3774805 | 0.79 | PIK3CD (0.39) | SMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | claimed |
| US-20250026758-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-01-23 | — | — | US | disclosed |
| CN-119112895-A | Muscarinic acetylcholine M1 receptor antagonists | 康蒂内乌姆医疗公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-112638381-B | Muscarinic acetylcholine M1 receptor antagonists | 康蒂内乌姆医疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-12054487-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2023067355-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-3846806-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| CN-112638381-A | Muscarinic acetylcholine M1 receptor antagonists | 帕珀莱恩医疗公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | USP30 2387/4885USP2 2496/4885SMN1; SMN2 1028/4885 |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | NISCH, BDKRB2, VIP | USP30 1738/4885USP2 1988/4885SMN1; SMN2 3177/4885 |
| US-12054487-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | USP30 2186/4885USP2 2885/4885SMN1; SMN2 1266/4885 |
| US-20250026758-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | USP30 2387/4885USP2 2496/4885SMN1; SMN2 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.